Genomma Lab Internacional B de C : 4Q-2021 Earnings Call Advisory
January 30, 2023 at 03:54 pm EST
Share
Investor Relations
T. +52 (55) 5081 0000 investor.relations@genommalab.com
Genomma Lab Internacional S.A.B. DE C.V.
Fourth Quarter & Full Year 2022 Earnings Call
Presenters:
Mr. Jorge Luis Brake, Chief Executive Officer
Mr. Antonio Zamora, Chief Financial Officer
Mr. Marco Sparvieri, Chief Operations Officer
Date:
Thursday, February 23, 2023
Time:
11:00 a.m. ET / 10:00 a.m. CST (Mexico City Time)
Webcast:
To register please click on here
(After register is completed you will receive an email confirmation with a
personal invitation)
Note:
Genomma Lab will report Fourth Quarter & Full Year 2022 Earnings Release on
Wednesday, February 22, 2023 after the Mexican Market (BMV) close.
About Genomma Lab Internacional
Genomma Lab Internacional, S.A.B. de C.V. is one of the leading pharmaceutical and personal care products companies in Mexico with an increasing international presence. Genomma Lab develops, sells and markets a broad range of premium branded products, many of which are leaders in the categories in which they compete in terms of sales and market share. Genomma Lab relies on the combination of a successful new product development process, a consumer-oriented marketing, a broad retail distribution network and a low-cost, highly flexible operating model.
Genomma Lab's shares are listed on the Mexican Stock Exchange under the ticker "LABB" (Bloomberg: LABB:MM).
Note on Forward-Looking Statements
This report may contain certain forward-looking statements and information relating to the Company that reflect the current views and/or expectations of the Company and its management with respect to its performance, business and future events. Forward looking statements include, without limitation, any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain words like "believe," "anticipate," "expect," "envisages," "will likely result," or any other words or phrases of similar meaning. Such statements are subject to a number of risks, uncertainties and assumptions. We caution you that a number of important factors could cause actual results to differ materially from the plans, objectives, expectations, estimates and intentions expressed in this presentation and in oral statements made by authorized officers of the Company. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
https://inversionistas.genommalab.com/
1
Attachments
Original Link
Original Document
Permalink
Disclaimer
Genomma Lab International SAB de CV published this content on 30 January 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 30 January 2023 20:53:02 UTC.
Genomma Lab Internacional SAB de CV is a Mexico-based over-the-counter pharmaceutical (OTC pharmaceutical), generic drugs (GD) and personal care products company. The Company is engaged in the development, distribution and marketing of a range of products within different brands, for such treatments as anti-acne, varicose vein, hair loss, sexual stimulation and influenza; as well as analgesics and antifungals. The Companyâs product portfolio includes such brands as Asepxia, Cicatricure, Goicoechea, Bengue, Diabet TX, Genoprazol, Goicotabs, Shot B, SilkaMedic, Siluet 40, Nikzon, X Ray, Next, Touch Me, Lomecan V and QG5, among others. The Company is a parent of a number of controlled entities, which have operations established in Mexico, the United States, Peru, Chile, Ecuador and Honduras, among others. In June 2014, the Company acquired 50% stake in Grupo Comercial e Industrial Marzam SA de CV.
GENOMMA LAB INTERNACIONAL, S.A.B. DE C.V. 
